RESUMEN
OBJECTIVE: To compare response rates and remission and survival times in dogs with lymphoma treated with a continuous, multiagent, doxorubicin-based chemotherapeutic protocol or with a short-term single-agent protocol incorporating doxorubicin. DESIGN: Nonrandomized controlled clinical trial. ANIMALS: 114 dogs with lymphoma. PROCEDURES: Dogs were treated with a chemotherapeutic protocol consisting of L-asparaginase, vincristine, cyclophosphamide, doxorubicin, methotrexate, and prednisolone (n=87) or doxorubicin alone (27). RESULTS: 63 of 86 (73%) dogs treated with the multiagent protocol (data on response was unavailable for 1 dog) and 14 of 27 (52%) dogs treated with the single-agent protocol had a complete remission. Dogs with lymphoma classified as substageAsunto(s)
Antibióticos Antineoplásicos/uso terapéutico
, Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico
, Enfermedades de los Perros/tratamiento farmacológico
, Doxorrubicina/uso terapéutico
, Linfoma/veterinaria
, Animales
, Enfermedades de los Perros/mortalidad
, Perros
, Femenino
, Linfoma/tratamiento farmacológico
, Linfoma/mortalidad
, Masculino
, Estadificación de Neoplasias/veterinaria
, Inducción de Remisión
, Análisis de Supervivencia
, Factores de Tiempo
, Resultado del Tratamiento